Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients
Chemical Communications2005Iss. 36, pp. 4601–4601
Citations Over TimeTop 1% of 2005 papers
P. Vishweshwar, Jennifer A. McMahon, Matthew L. Peterson, Magali B. Hickey, T.R. Shattock, Michael J. Zaworotko
Abstract
The carboxylic acid-primary amide supramolecular heterosynthon is exploited for the generation of pharmaceutical co-crystals that contain two active pharmaceutical ingredients that are polymorphic in their pure forms.
Related Papers
- → Polymorphism and Crystallization of Active Pharmaceutical Ingredients (APIs)(2009)211 cited
- → Making crystals from crystals: a green route to crystal engineering and polymorphism(2005)206 cited
- → Controlled Release(1992)4 cited
- → Evaluation of the presence of polymorphic forms and influence on the dissolution profile of Tenoxicam in active pharmaceutical ingredient and formulations(2019)1 cited
- → Sustained Active Ingredient Release from Drugs: Statistical Model for Random Sample Assessment In Vitro(1989)